Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for 161Tb-KLK3-mAb Phase I Clinical Trial in Australia

Friday, June 27, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has entered into a clinical supply agreement with Cyclotek for the 161Tb-KLK3-mAb Phase I clinical trial in Australia. This collaboration marks a significant step in advancing their therapeutic offerings. The trial aims to evaluate the efficacy and safety of the new treatment in patients.
Price reaction · baseline $4.7188 (2025-06-27 close) · hit after-hours · 1 other RADX headline(s) in the window, move may be shared
day 0 close
-1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has signed a clinical supply agreement.
  • The agreement is for a Phase I clinical trial in Australia.
  • This trial involves the innovative 161Tb-KLK3-mAb treatment.

Full Press Release Details

• Announcements
• PDF
• June 27, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• May 27, 2022
• Announcements
• September 9, 2022
• Announcements
• September 28, 2023
• Announcements
• August 24, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of the clinical supply agreement?

The agreement is to support the Phase I clinical trial of 161Tb-KLK3-mAb.

Who is involved in the clinical trial?

Radiopharm Theranostics and Cyclotek are collaborating on the trial.

Where is the trial taking place?

The Phase I clinical trial is being conducted in Australia.

What treatment is being tested in this trial?

The trial is testing the innovative treatment 161Tb-KLK3-mAb.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Cyclotek 161Tb-KLK3-mAb Phase I trial clinical supply agreement
Last updated: Jun 27, 2025